Angioid Streaks Clinical Trial
Official title:
Ranibizumab Therapy for Choroidal Neovascularization Associated With Angioid Streaks
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
Choroidal neovascularization is a hallmark of angioid streaks, and presumably VEGF-driven. Ranibizumab has been shown to be effective in CNV secondary to age-related macular degeneration. Therefore, we hypothesize that ranibizumab may be efficacious in the treatment of CNV secondary to angioid streaks ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00406250 -
Intravitreal Bevacizumab in Agioid Streaks
|
Phase 1 | |
| Active, not recruiting |
NCT00599820 -
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
|
Phase 3 | |
| Withdrawn |
NCT01256580 -
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
|
N/A |